High-dose aldesleukin in renal cell carcinoma: Long-term survival update

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Fisher, Richard I ^a   Rosenberg, Steven A ^b   Sznol, Mario ^b   Parkinson, David R ^b,c   Fyfe, Gwendolyn ^c,d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d GENENTECH INC   (United States)

Author keywords

Immunotherapy; Interleukin 2; Renal cell carcinoma

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031406878     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
2. Fisher RI, Coltman CA, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 1988;108:518-523.
3. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13: 688-696.
4. Margolin KA, Rayner AA, Hawkins MJ et al. Interleukin-2 and lymphokine activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-498.
5. Fyfe GA, Fisher RI, Rosenberg SA et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14:2410-2411.
6. Parkinson DR, Fisher RI, Rayner AA et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-acrivated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 1990;8:1630-1636.
7. Weiss GR, Margolin KA, Aronson FR et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275-281.
8. Atkins MB, Sparano J, Fisher RI et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-670.
9. Dutcher JP, Fisher RI, Weiss G et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group study. Cancer J Sci Am 1997;3:157-162.
10. Margolin K, Atkins MB, Sparano J et al. Prospective randomized trial of lisofylline for the prevention of toxicity of high-dose interleukin-2 therapy for advanced renal cell cancer and malignant melanoma. Clinical Cancer Research 1997;3:565-572.